uniQure N.V. (QURE)
uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
| Company Name: |
uniQure N.V. |
| Website: |
www.uniqure.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding QURE: |
8 |
| Total Market Value Held by ETFs: |
$4.98M |
| Total Market Capitalization: |
$227.00M |
| % of Market Cap. Held by ETFs: |
2.19% |
|
|
April 18, 2024 • 4:44 AM Eastern
Buy (3.43 out of 4)
100th percentile
|
|
Free QURE Email Alerts:
